Nanologica AB

As of June 30, 2026, Nanologica AB carries a market capitalization of 159.12M, placing it among publicly traded companies globally. Its enterprise value stands at 193.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nanologica AB's next confirmed earnings release is scheduled for November 26, 2026.

As of June 30, 2026, Nanologica AB has 328.77M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nanologica AB maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Nanologica AB's stock has declined approximately 82.24% over the past 52 weeks. The 50-day moving average sits at 0.34, while the 200-day moving average is 0.46.

As of June 30, 2026, Nanologica AB holds 19.06M in cash and equivalents against 53.63M in total debt, resulting in a net debt position of -19.06M. Total book value stands at 156.43M, with working capital of 81.09M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Nanologica AB's most recent stock split took place on March 6, 2026 with a 803:810 split ratio.